Correspondence |

Targets of the Peroxisome Proliferator–Activated Receptor γ Agonist Trials for the Prevention of Alzheimer Disease

Takashi Sakurai, MD, PhD
Arch Neurol. 2011;68(4):542-543. doi:10.1001/archneurol.2011.57.
Text Size: A A A
Published online


The recent article by Geldmacher et al1 describes the peroxisome proliferator–activated receptor γ (PPARγ) agonist pioglitazone trial for patients with Alzheimer disease (AD). Pioglitazone was generally well tolerated during 18 months of exposure, but no efficacy was demonstrated on clinical outcome measures.

Thiazolidinediones have beneficial effects in animal models of AD, but the efficiency of PPARγ agonists for treatment in mild to moderate AD remains unclear. Beneficial effects of rosiglitazone were first described in APOE-4 –negative patients with AD.2 However, repeated trials with rosiglitazone have not demonstrated consistent results.2 Pioglitazone treatment in diabetic patients with AD improved cognitive function as well as regional cerebral blood flow after a 6-month interval.3 I have experienced several cases in which pioglitazone has been protective against cognitive decline in AD over 24 months.4 In this connection, there might be unidentified factors that influence thiazolidinedione therapy for AD.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario